title: [A retrospective study of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy in patients with stage III colon cancer].
abstract: OBJECTIVE
  To perform a retrospective analysis of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy for stage III colon cancer in order to evaluate both treatment efficacy and toxicity.
  
  
  METHODS
  Between 2003 and 2009, 273 stage III colon cancer patients underwent surgery in our institute, and we studied 156 of them.
  
  
  RESULTS
  Patients' median age was 72 years old; 87 men and 69 women. Of all patients, 119 had stage IIIa and 37 had stage IIIb. The 3-year disease, free survival rates for stage III, stage IIIa and stage IIIb patients were 73. 9%and 80. 6%and 51. 4%, respectively, and the 3-year overall survival rates for stage III was 97. 6%. With regard to toxicity, liver function disorder was observed in 9. 6%of the patients as the most frequent adverse event, but there was no grade 3 or 4 toxicity.
  
  
  CONCLUSIONS
  UFT and oral leucovorin plus PSK combination adjuvant chemotherapy for stage III colon cancer showed a good response especially for stage III a.
authors.affiliation: Dept. of Surgery, Toranomon Hospital.
authors.forename: Kenji
authors.initials: K
authors.lastname: Tomizawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kumamoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hanaoka
authors.forename: Shigeo
authors.initials: S
authors.lastname: Toda
authors.forename: Jin
authors.initials: J
authors.lastname: Moriyama
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Matoba
authors.forename: Hiroya
authors.initials: H
authors.lastname: Kuroyanagi
authors.forename: Masaji
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Harushi
authors.initials: H
authors.lastname: Udagawa
authors.forename: Goro
authors.initials: G
authors.lastname: Watanabe
authors.forename: Toshihito
authors.initials: T
authors.lastname: Sawada
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002955:Leucovorin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D009367:Neoplasm Staging; D011134:Polysaccharides / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D005641:Tegafur / Q000191:economics / Q000627:therapeutic use; D014498:Uracil / Q000191:economics / Q000627:therapeutic use
chemical_list: D011134:Polysaccharides; D005641:Tegafur; D014498:Uracil; D002955:Leucovorin